Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases
Next-generation CRISPR genome editing β’ allogeneic CAR-T cell therapies β’ iPSC-derived NK cell therapies β’ oncology
51 - 200
π° $125M Post-IPO Equity on 2023-07
November 8
51 - 200
Manage clinical trials for Caribou's advanced genome-editing therapies.
πΊπΈ United States β Remote
π° $125M Post-IPO Equity on 2023-07
β³ Contract/Temporary
π΄ Lead
π Senior
π§ͺ Clinical Research
π½ H1B Visa Sponsor
September 23
51 - 200
Field Medical Affairs Director for Caribou's cellular therapy pipeline.
πΊπΈ United States β Remote
π΅ $200k - $220k / year
π° $125M Post-IPO Equity on 2023-07
β° Full Time
π΄ Lead
π¨ββοΈ Medical Director
π½ H1B Visa Sponsor